Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

Abstract Background Long-term antiviral treatments are associated with a significantly lower hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients by reducing HBV DNA concentrations. However, it is still controversial whether antiviral strategies affect HCC development in an...

Полное описание

Библиографические подробности

Главные авторы:	Ze-Hong Huang, Gui-Yang Lu, Ling-Xian Qiu, Guo-Hua Zhong, Yue Huang, Xing-Mei Yao, Xiao-Hui Liu, Shou-Jie Huang, Ting Wu, Quan Yuan, Ying-Bin Wang, Ying-Ying Su, Jun Zhang, Ning-Shao Xia
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2022-03-01
Серии:	BMC Cancer
Предметы:	Chronic hepatitis B Hepatocellular carcinoma Entecavir Tenofovir Cirrhosis
Online-ссылка:	https://doi.org/10.1186/s12885-022-09413-7
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!